These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33293041)

  • 1. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
    Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
    Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
    Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
    Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
    Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
    Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.
    Michielsen LA; Wisse BW; Kamburova EG; Verhaar MC; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; van Zuilen AD
    Nephrol Dial Transplant; 2019 Jun; 34(6):1056-1063. PubMed ID: 30365008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leukocyte antigen compatibility and incidence of donor-specific antibodies in pediatric liver transplant recipients.
    Melere MU; Feier FH; Neumann J; Kalil AN; Montagner JM; Nader LS; da Silva CS; Junior MAF; Coral GP; Bobsin GP; Ferreira CT
    World J Gastroenterol; 2024 Sep; 30(33):3837-3845. PubMed ID: 39351427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo donor-specific HLA antibodies reduce graft survival rates and increase the risk of kidney transplant rejection: A single-center retrospective study.
    Liu W; Zhao J; Kang ZY; Xiao YL; Yang L; Liu C; Li DH
    Transpl Immunol; 2021 Oct; 68():101430. PubMed ID: 34147608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous Immunoglobulins Alone for the Desensitization of Lung Transplant Recipients with Preformed Donor Specific Antibodies and Negative Flow Cytometry Crossmatch.
    Abdulqawi R; Alawwami M; Aldosari O; Aldosari Z; Alhuqbani M; Saleh RA; Esendagli D; Aldakhil H; De Vol EB; Alkattan K; Marquez KAH; Saleh W; Sandoqa S; Al-Mutairy EA
    Clin Transplant; 2024 Jul; 38(7):e15374. PubMed ID: 38979724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Year Outcomes of Living Related Kidney Transplant in Patients With Preformed HLA Donor-Specific Antibodies: A Single-Center Experience in Malaysia.
    Jalalonmuhali M; Ng KP; Mohd Shariff NH; Lee YW; Wong AH; Gan CC; Lim SK
    Transplant Proc; 2020; 52(6):1718-1722. PubMed ID: 32448671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
    Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
    Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
    Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
    Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of HLA molecular level mismatching in ethnically diverse kidney transplant recipients receiving a steroid-sparing immunosuppression protocol.
    Santos E; Spensley K; Gunby N; Worthington J; Roufosse C; Anand A; Willicombe M
    Am J Transplant; 2024 Jul; 24(7):1218-1232. PubMed ID: 38403189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
    Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
    Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
    Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal transplant outcomes and de novo donor-specific anti-human leukocyte antigen antibodies: a systematic review.
    Sharma A; Lewis JR; Lim WH; Palmer S; Strippoli G; Chapman JR; Alexander SI; Craig JC; Wong G
    Nephrol Dial Transplant; 2018 Aug; 33(8):1472-1480. PubMed ID: 29660004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.